Form 4: CEO John Kao Sells 180,000 ALHC Shares

Alignment Healthcare CEO John Kao sold 180,000 shares of common stock for approximately $2.94 million under a pre-arranged 10b5-1 trading plan.

Summary

• John E. Kao, Chief Executive Officer and Director of Alignment Healthcare, Inc. (ALHC), reported the sale of 180,000 shares of common stock.
• The transaction occurred on November 10, 2025.
• Shares were sold at a weighted-average price of $16.3154 per share, with individual transaction prices ranging from $16.01 to $16.54.
• The total value of the shares sold is approximately $2,936,772.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2025.
• Following the transaction, Mr. Kao directly owns 2,839,942 shares and indirectly owns 2,526,726 shares through the JEK Trust.

Sentiment

Score: 4

Explanation: A CEO selling a significant number of shares, even under a 10b5-1 plan, can be viewed with slight caution by the market. However, the pre-planned nature mitigates immediate negative speculation, suggesting personal financial management rather than a reaction to adverse company news. It is not a strong positive signal, nor an immediate red flag.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new, undisclosed information.

Negatives

• A significant sale of 180,000 shares by the Chief Executive Officer and Director could be perceived negatively by some investors, potentially signaling a lack of confidence or a desire to diversify holdings.

Risks

• Investor perception risk: Large insider sales, even if pre-planned, can sometimes lead to negative market sentiment or speculation about the company's future prospects.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing reports an insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the healthcare sector. Insider sales are common across industries for various personal financial planning reasons.

Related Party Transactions

• Indirect beneficial ownership of 2,526,726 shares is held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee. This represents a related party holding structure.

Stakeholder Impact

• Shareholders: May interpret the CEO's sale as a signal, potentially leading to minor downward pressure or increased scrutiny of the stock, although the 10b5-1 plan mitigates some concerns.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this insider trading report, as it pertains to personal stock transactions of an executive.

Key Dates

Recommendation

While a CEO selling shares can sometimes be a negative signal, this transaction was conducted under a pre-arranged 10b5-1 plan, which suggests personal financial planning rather than a reaction to new, undisclosed negative information. Given the planned nature and the remaining significant direct and indirect holdings, it does not warrant an immediate 'sell' recommendation, but it also doesn't provide a strong 'buy' signal. Investors should 'hold' and monitor future company performance and insider activity.

Keywords

Alignment Healthcare, ALHC, John E. Kao, Insider Sale, Form 4, CEO, Director, Stock Sale, 10b5-1 Plan, Healthcare